Ovarian Cancer

  • Renata Félix da Justa
  • Ramon Andrade De MelloEmail author


Ovarian cancer is the fifth most common type of cancer in women and the fourth most common cause of cancer death in them. The overall 5-year relative survival currently is between 30% and 40% across the globe. However, the disease typically presents at late stage when this rate is only 29%. Despite the public health significance, the etiology of this lethal disease is not completely understood but many associated risk factors have been identified. Ovarian tumors benign or malignant originate from one of three cell types: epithelial cells, stromal cells or germ cells. More than 90% of malignant ovarian tumors are of epithelial origin, 5–6% of tumors constitute sex cord-stromal tumors, and 2–3% are germ cell tumors. Staging of ovarian cancer is surgical and the International Federation of Gynecology and Obstetrics staging remains the most powerful indicator of prognosis. Primary treatment for presumed ovarian cancer consists of appropriate surgical stagin and debulking, followed in most patients by systemic chemotherapy with or without Targeted Therapies. In the relapse setting, treatment considerations include the disease-free interval, existing toxicities from first-line treatment and volume of disease at the time of relapse.


Ovarian carcinoma Review Management Epidemiology 


  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2013) GLOBOCAN 2012; Cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer. Accessed 03 Dec 2017
  2. 2.
    Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W et al (2010) SEER cancer statistics review, 1975–2008. National Cancer Institute. Accessed 03 Dec 2017
  3. 3.
    Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS et al (2015) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25676887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977–1010. Scholar
  4. 4.
    Scully RE, Sobin LH, Serov SF (1999) Histological typing of ovarian tumours. Springer, Berlin/Heidelberg/New YorkCrossRefGoogle Scholar
  5. 5.
    Mackay HJ, Brady MF, Oza AM et al (2010) Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 20:945–952CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Shimizu Y, Kamoi S, Amada S et al (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893–901CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20:207–225CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Prat J (2012) Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 460:237–249CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615CrossRefGoogle Scholar
  10. 10.
    Diaz-Padilla I, Malpica AL, Minig L et al (2012) Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 126:279–285CrossRefGoogle Scholar
  11. 11.
    Schmeler KM, Sun CC, Bodurka DC et al (2008) Neoadjuvant chemotherapy for lowgrade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108:510–514CrossRefGoogle Scholar
  12. 12.
    Wiegand KC, Shah SP, Al-Agha OM et al (2010) ARID1A mutations in endometriosisassociated ovarian carcinomas. N Engl J Med 363:1532–1543CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    McCluggage WG (2011) Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43:420–432CrossRefGoogle Scholar
  14. 14.
    Bell D, Berchuck A, Birrer M et al (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615CrossRefGoogle Scholar
  15. 15.
    Vang R, Shih I-M, Kurman RJ (2013) Fallopian tube precursors of ovarian low- and highgrade serous neoplasms. Histopathology 62:44–58CrossRefGoogle Scholar
  16. 16.
    Carlson JW, Miron A, Jarboe EA et al (2008) Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous câncer prevention. J Clin Oncol 26:4160–4165CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G (1994) Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 170:81–85CrossRefGoogle Scholar
  18. 18.
    Garcia-Soto AE, Boren T, Wingo SN et al (2012) Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol 206:242.e241–242.e245CrossRefGoogle Scholar
  19. 19.
    Timmers PJ, Zwinderman AH, Coens C et al (2010) Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer 46:880–884CrossRefGoogle Scholar
  20. 20.
    Cass I, Li AJ, Runowicz CD et al (2001) Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 80:56–61CrossRefPubMedGoogle Scholar
  21. 21.
    Maggioni A, Benedetti Panici P, Dell’Anna T et al (2006) Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 95:699–704CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fruscio R, Corso S, Ceppi L et al (2013) Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol 24:138–144CrossRefPubMedGoogle Scholar
  23. 23.
    du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes dês Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244CrossRefPubMedGoogle Scholar
  24. 24.
    van der Burg ME, van Lent M, Buyse M et al (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332:629–634CrossRefPubMedGoogle Scholar
  25. 25.
    Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953CrossRefGoogle Scholar
  26. 26.
    Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C et al (2017) LION: lymphadenectomy in ovarian neoplasms—a prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol 35 (suppl):abstr 5500Google Scholar
  27. 27.
    du Bois A, Reuss A, Harter P et al (2010) Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 28:1733–1739CrossRefGoogle Scholar
  28. 28.
    Panici PB, Maggioni A, Hacker N et al (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97:560–566CrossRefGoogle Scholar
  29. 29.
    Rose PG, Nerenstone S, Brady MF et al (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489–2497CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Harter P, Hahmann M, Lueck HJ et al (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16:1324–1330CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Zang RY, Harter P, Chi DS et al (2011) Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 105:890–896CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Fotopoulou C, Zang R, Gultekin M et al (2013) Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol 20:1348–1354CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Winter-Roach BA, Kitchener HC, Dickinson HO (2009) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 8(3):CD004706Google Scholar
  34. 34.
    Swart AC (2007) Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian câncer (ICON1) J Clin Oncol 25(18 Suppl):Abstr 5509Google Scholar
  35. 35.
    Chan JK, Tian C, Fleming GF et al (2010) The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a gynecologic oncology group study. Gynecol Oncol 116:301–306CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    du Bois A, Lueck H, Meier W et al (1999) Cisplatin/paclitaxel VS arboplatin/paclitaxel in ovarian cancer: update of an AGO trial. Proc Am Soc Clin Oncol 18(356ª Suppl):abstr 1374Google Scholar
  37. 37.
    Neijt JP, Engelholm SA, Tuxen MK et al (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084–3092CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21:3194–3200CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Alvarez RD, Plaxe SC, Armstrong DK et al (2017) Ovarian cancer National Comprehensive Cancer Network 2017; Version 4.Google Scholar
  40. 40.
    Pignata S, Scambia G, Ferrandina G et al (2011) Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29:3628–3635CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Speert H (1956) Obstetrical-gynecological eponyms: Fritz Brenner and Brenner tumors of the ovary. Cancer 9:217–221CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    von Numers C (1945) A contribution to the case knowledge and histology of the Brenner tumor: do malignant forms of the Brenner tumor also occur? Acta Obstet Gynecol Scand 25:114–127CrossRefGoogle Scholar
  45. 45.
    Ali R, Seidman J, Luk M, Kalloger S, Gilks C (2012) Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant Brenner tumor. Int J Gynecol Pathol 31:499–506CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23:41–44CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hull M, Campbell G (1973) The malignant Brenner tumor. Obstet Gynecol 42:527–534CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Yang B, Yu Y, Chen J et al (2018) Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant—a Chinese retrospective cohort study among 148 cases. Front Med 12(5):1–9Google Scholar
  49. 49.
    Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM et al (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109(2):221–227CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Mitchell DG, Javitt MC, Glanc P, Bennett GL, Brown DL, Dubinsky T et al (2013) ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol 10:822–827. Scholar
  51. 51.
    Im SS, Gordon AN, Buttin BM, Leath CA, Gostout BS, Shah C et al (2005) Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 105(1):35–41CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    American College of Obstetricians and Gynecologists (2007) Management of adnexal masses. ACOG Pract Bull Obstet Gynecol 110(1):201–214Google Scholar
  53. 53.
    Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C et al (2008) Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 31:681–690. Scholar
  54. 54.
    Gregory JJ, Finlay JL (1999) Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Drugs 57(4):463–467CrossRefGoogle Scholar
  55. 55.
    Kawai M, Furuhashi Y, Kano T, Misawa T, Nakashima N, Hattori S et al (1990) Alpha-fetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol 39(2):160–166CrossRefGoogle Scholar
  56. 56.
    Iyer VR, Lee SI (2010) MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol 194(2):311–321. Scholar
  57. 57.
    Bristow RE, Chang J, Ziogas A, Anton-Culver H (2013) Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 121(6):1226–1234. Scholar
  58. 58.
    Erickson BK, Martin JY, Shah MM, Straughn JM, Leath CA (2014) Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center. Gynecol Oncol 133(2):142–146. Scholar
  59. 59.
    Ledermann JA, Raja FA, Fotopoulou C et al (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl):vi24–vi32PubMedGoogle Scholar
  60. 60.
    Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H (2015) Impact of National Cancer Institute comprehensive cancer centers on ovarian cancer treatment and survival. J Am Coll Surg 220(5):940–950. Scholar
  61. 61.
    Monk BJ, Anastasia PJ (2016) Ovarian Cancer: current treatment and patient management. J Adv Pract Oncol 7(3):271–273PubMedPubMedCentralGoogle Scholar
  62. 62.
    Robert AB, Mark FB, Michael AB, Gini FF, Bradley JM et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483CrossRefGoogle Scholar
  63. 63.
    Devansu T, James JJ, Ritu S, Deborah KA, Maurie M, Thomas H et al (2015) Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol Off J Am Soc Clin Oncol 33:1460–1466CrossRefGoogle Scholar
  64. 64.
    Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener HC, Lopes T et al (2013) Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. J Clin Oncol 31:5500Google Scholar
  65. 65.
    Sean K, Jane H, Matthew N, Gordon CJ, Henry K, Tito L et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249–257CrossRefGoogle Scholar
  66. 66.
    Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP et al (2013) Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 131(1):21–26. Scholar
  67. 67.
    Schorge JO, Eisenhauer EE, Chi DS (2012) Current surgical management of ovarian cancer. Hematol Oncol Clin North Am 26(1):93–109. Scholar
  68. 68.
    du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M et al (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7–viii12PubMedGoogle Scholar
  69. 69.
    Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25(20):2873–2883CrossRefGoogle Scholar
  70. 70.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C et al (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103(3):1083–1090CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Chi DS, Bristow RE, Armstrong DK, Karlan BY (2011) Is the easier way ever the better way? J Clin Oncol 29(31):4073–4075. Scholar
  72. 72.
    Liu CS, Nagarsheth NP, Nezhat FR (2009) Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer? J Minim Invasive Gynecol 16(3):250–262. Scholar
  73. 73.
    Mori KM, Neubauer NL (2013) Minimally invasive surgery in gynecologic oncology. ISRN Obstet Gynecol 12(2013):312982. Scholar
  74. 74.
    Rutten MJ, Meurs HSV, Vrie RV, Gaarenstroom KN, Naaktgeboren CA, Gorp TV, Brugge HGT et al (2017) Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J Clin Oncol 35(6):613–621. Scholar
  75. 75.
    Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL et al (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol 143(1):3–15. Scholar
  76. 76.
    Morrison J, Haldar K, Kehoe S, Lawrie TA (2012) Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 15(8):CD005343. Scholar
  77. 77.
    Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P (2009) Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 21(1):CD006014. Scholar
  78. 78.
    Landrum LM, Java J, Mathews CA, Lanneau GS Jr, Copeland LJ, Armstrong DK, Walker JL (2013) Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 130(1):12–18. Scholar
  79. 79.
    Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JN, Iyer RB, Zhou Q et al (2017) A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian câncer. Gynecol Oncol 145:27–31CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Mackay H, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Gourley C et al (2016) OV21/PETROC: a randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). J Clin Oncol 34(18 suppl):LBA5503–LBA5503CrossRefGoogle Scholar
  81. 81.
    Garcia YG, Juan AD, Mendiola C, Ginesta MPB, Prat A, Santaballa A et al (2017) Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL). J Clin Oncol 35(15 suppl):5508–5508CrossRefGoogle Scholar
  82. 82.
    Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG et al (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322(15):1021–1027CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Högberg T, Glimelius B, Nygren P et al (2001) A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 40(2–3):340–360CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS et al (2006) Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 108(3 Pt 1):521–528CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M et al (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer 24(9 Suppl 3):S14–S19. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Renata Félix da Justa
    • 1
  • Ramon Andrade De Mello
    • 2
    • 3
    Email author
  1. 1.Division of Surgical OncologyHaroldo Juaçaba Hospital, Ceará Cancer InstituteFortalezaBrazil
  2. 2.Division of Medical OncologyFederal University of São Paulo (UNIFESP) & Hospital Israelita Albert EinsteinSão PauloBrazil
  3. 3.Department of Biomedical Sciences and MedicineUniversity of AlgarveFaroPortugal

Personalised recommendations